Home
>
US Stocks
>
Cullinan Oncology Inc

Cullinan Oncology Inc (CGEM)

$10.28

+0.16

(+1.58%)▲

Market is closed - opens 7 PM, 01 Jun 2023

Insights on Cullinan Oncology Inc

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 43.0% return, outperforming this stock by 48.3%

Performance

  • $10.05
    $10.48
    $10.28
    downward going graph

    2.24%

    Downside

    Day's Volatility :4.06%

    Upside

    1.86%

    downward going graph
  • $7.78
    $15.89
    $10.28
    downward going graph

    24.32%

    Downside

    52 Weeks Volatility :51.04%

    Upside

    35.31%

    downward going graph

Returns

PeriodCullinan Oncology IncSector (Health Care)Index (Russel 2000)
3 Months
-10.36%
-0.3%
-6.7%
6 Months
-18.58%
-8.8%
-6.2%
1 Year
-5.33%
-4.2%
-5.1%
3 Years
-66.17%
23.0%
26.9%

Highlights

Market Capitalization
398.3M
Book Value
$12.34
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.34
PE Ratio
7.55
Wall Street Target Price
28.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.03%
Return On Equity TTM
14.13%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
18.9M
EBITDA
-160.1M
Diluted Eps TTM
1.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.67
EPS Estimate Next Year
-4.47
EPS Estimate Current Quarter
-0.98
EPS Estimate Next Quarter
-0.72

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Cullinan Oncology Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 177.24%

Current $10.28
Target $28.50

Technicals Summary

Sell

Neutral

Buy

Cullinan Oncology Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cullinan Oncology Inc
Cullinan Oncology Inc
-1.65%
-18.58%
-5.33%
-66.17%
33633.33%
Moderna, Inc.
Moderna, Inc.
-3.38%
-26.73%
-11.31%
107.29%
592.96%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.68%
-3.07%
9.61%
21.54%
142.61%
Seagen, Inc.
Seagen, Inc.
-2.59%
59.82%
42.99%
22.0%
220.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.71%
2.81%
21.09%
13.49%
111.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cullinan Oncology Inc
Cullinan Oncology Inc
7.55
7.55
NA
-4.67
0.14
-0.21
0.0
12.34
Moderna, Inc.
Moderna, Inc.
11.22
11.22
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.53
26.53
0.41
13.64
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cullinan Oncology Inc
Cullinan Oncology Inc
Buy
$398.3M
33633.33%
7.55
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.1B
592.96%
11.22
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
142.61%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.3B
220.73%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.0B
111.23%
26.53
35.4%

Institutional Holdings

  • MPM Oncology Impact Management LP

    19.44%

  • CHI Advisors LLC

    8.51%

  • Bvf Inc

    8.13%

  • Vanguard Group Inc

    6.49%

  • BlackRock Inc

    6.37%

  • American International Group Inc

    3.14%

Company Information

Cullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.

Organization
Cullinan Oncology Inc
Employees
62
CEO
Mr. Nadim Ahmed
Industry
Other Consumer Services

Discover More

FAQs